Human health

Overview
Right now, our human health project pipeline is focused on tackling one of the largest health challenges of our time – antimicrobial resistance. We are targeting biofilms with a novel approach, as these continue to drive this global healthcare challenge. 

Respiratory Infections in Cystic Fibrosis
Neem's lead candidate NX-AS-401 is a potential new treatment for chronic lung infections in patients with cystic fibrosis. It is designed to help eradicate the Pseudomonas aeruginosa bacteria infections that are the key cause of death for cystic fibrosis patients.

NX-AS-401 has a novel mechanism of action. As a quorum sensing inhibitor it disrupts communication between bacteria, thereby preventing them from forming the film that is crucial in protecting them from current anti-Pseudomonal antibiotics.

Infection Control in Wounds
Hard-to-heal wounds are those that fail to heal within 12 weeks. These wounds are frequently complex and management can therefore be lengthy and costly both for individuals and societies.

Unfortunately, current prevalence figures for infected hard-to-heal wounds are set to rise in coming years as more of us live longer and the effects of chronic lifestyle-related diseases such as diabetes and obesity take hold.

Control of infection in these wounds is key if the right conditions are to be created for them to heal. Neem’s candidate NX-AS-911 is a potential new treatment for this challenging situation. It disrupts communication between the biofilm forming Staphylociccus aureus and Pseudomonas aeruginosa bacteria that are frequently found in these wounds. In turn, this prevents these bacteria from forming the biofilm that is crucial in protecting themselves both from current antibiotics that may be used and from the body's own immune system.

 

 

Human health

Overview
Right now, our human health project pipeline is focused on tackling one of the largest health challenges of our time – antimicrobial resistance. We are targeting biofilms with a novel approach, as these continue to drive this global healthcare challenge. 

Respiratory Infections in Cystic Fibrosis
Neem's lead candidate NX-AS-401 is a potential new treatment for chronic lung infections in patients with cystic fibrosis. It is designed to help eradicate the Pseudomonas aeruginosa bacteria infections that are the key cause of death for cystic fibrosis patients.

NX-AS-401 has a novel mechanism of action. As a quorum sensing inhibitor it disrupts communication between bacteria, thereby preventing them from forming the film that is crucial in protecting them from current anti-Pseudomonal antibiotics.

Infection Control in Wounds
Hard-to-heal wounds are those that fail to heal within 12 weeks. These wounds are frequently complex and management can therefore be lengthy and costly both for individuals and societies.

Unfortunately, current prevalence figures for infected hard-to-heal wounds are set to rise in coming years as more of us live longer and the effects of chronic lifestyle-related diseases such as diabetes and obesity take hold.

Control of infection in these wounds is key if the right conditions are to be created for them to heal. Neem’s candidate NX-AS-911 is a potential new treatment for this challenging situation. It disrupts communication between the biofilm forming Staphylociccus aureus and Pseudomonas aeruginosa bacteria that are frequently found in these wounds. In turn, this prevents these bacteria from forming the biofilm that is crucial in protecting themselves both from current antibiotics that may be used and from the body's own immune system.